SCHEMBL3312130

SCHEMBL3312130

COC(=O)CNCc1ccccc1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.48
KDM4E B2RXH2 7/20 0.48
HPGD P15428 5/20 0.48
RCE1 Q9Y256 1/20 0.48
CFTR P13569 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TSHR P16473 1/20 0.43
PDCD1 Q15116 2/20 0.42
CD274 Q9NZQ7 2/20 0.42
KMT2A Q03164 3/20 0.40
POLB P06746 1/20 0.40
FDPS P14324 1/20 0.39
USP2 O75604 2/20 0.39
MEN1 O00255 2/20 0.39
APOBEC3A P31941 1/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
LMNA P02545 1/20 0.39
HDAC3 O15379 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10682599 0.86 PPID (0.48) ALDH1A1KDM4EHPGDRCE1HSD17B10
SCHEMBL1279543 0.81 TSHR (0.60) KDM4EHSD17B10TSHR
SCHEMBL6341212 0.80 KDM4E (0.57) ALDH1A1KDM4EHPGDTSHRKMT2A
SCHEMBL20564087 0.80 KMT2A (0.55) ALDH1A1KDM4ETSHRKMT2AMEN1
Hydrochloric Acid SCHEMBL8303604 0.80 HPGD (0.49) ALDH1A1KDM4EHPGDTSHRPDCD1
SCHEMBL7058131 0.80 NPC1 (0.54) ALDH1A1KDM4EKMT2AMEN1
SCHEMBL19910422 0.80 KMT2A (0.52) ALDH1A1KDM4EKMT2AMEN1LMNA
SCHEMBL11497779 0.79 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDRCE1HSD17B10
SCHEMBL644296 0.79 ALDH1A1 (0.49) ALDH1A1KDM4EHPGDRCE1CFTR
Hydrochloric Acid SCHEMBL6341211 0.79 CHRM2 (0.58) ALDH1A1KDM4EKMT2APOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594307-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2025-08-06 EP disclosed
WO-2024073426-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-04-04 WO disclosed
US-20140187550-A1 BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS NOVARTIS AG (CH) 2014-07-03 US disclosed
US-8633211-B2 Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions NOVARTIS AG (CH) 2014-01-21 US disclosed
US-20100113774-A1 BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS NOVARTIS AG (CH) 2010-05-06 US disclosed
EP-2132186-A1 BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS Novartis AG (CH) 2009-12-16 EP disclosed
WO-2008107436-A1 BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS NOVARTIS AG (CH) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113774-A1 BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS S1PR3, S1PR1, S1PR2 ALDH1A1 1798/4885KDM4E 3052/4885HPGD 2063/4885
US-20140187550-A1 BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS S1PR3, S1PR1, S1PR2 ALDH1A1 1837/4885KDM4E 2815/4885HPGD 2160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.